FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Nygren

Research Profile

Chemicals & Drugs

Anatomy

Procedures

Physiology

Disorders

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Bo Hultman; Pehr Lind; Bengt Glimelius; Ulf Haglund; Peter Nygren; Magnus Sundbom; Haile Mahteme
Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy.
Malin Jarvius; Pädraig D'Arcy; Mårten Fryknäs; Joachim Gullbo; Caroline Haglund; Stig Linder; Peter Nygren; Linda Rickardson; Chao Sun; Rolf Larsson
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Saadia B Hassan; Kefei Hu; Bror Morein; Saideh Berenjian; Joachim Gullbo; Peter Nygren
The Nanoparticulate Quillaja Saponin BBE is selectively active towards renal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Nygren (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Bo Hultman; Pehr Lind; Bengt Glimelius; Ulf Haglund; Peter Nygren; Magnus Sundbom; Haile Mahteme
Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy.
Acta oncologica (Stockholm, Sweden) 2013;52(4):824-30.
2013: Malin Jarvius; Pädraig D'Arcy; Mårten Fryknäs; Joachim Gullbo; Caroline Haglund; Stig Linder; Peter Nygren; Linda Rickardson; Chao Sun; Rolf Larsson
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Biochemical and biophysical research communications 2013;431(2):117-23.
2013: Saadia B Hassan; Kefei Hu; Bror Morein; Saideh Berenjian; Joachim Gullbo; Peter Nygren
The Nanoparticulate Quillaja Saponin BBE is selectively active towards renal cell carcinoma.
Anticancer research 2013;33(1):143-51.
2012: Peter H Cashin; Wilhelm Graf; Peter Nygren; Haile Mahteme
Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study.
Annals of surgery 2012;256(6):1078-83.
2012: Hanna Andréasson; Bengt Glimelius; Wilhelm Graf; Peter Nygren; Haile Mahteme
Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2012;38(10):962-8.
2012: Henning Karlsson; Rolf Larsson; Mårten Fryknäs; Peter Nygren
Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system.
Experimental cell research 2012;318(13):1577-85.
2012: P H Cashin; Wilhelm Graf; Peter Nygren; Haile Mahteme
Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2012;38(6):509-15.
2012: Håkan Andréasson; Bengt Glimelius; Wilhelm Graf; Peter Nygren; Xiao-Feng Sun; Alkwin Wanders; Roger Willén; Zhi-Yong Zhang; Haile Mahteme
Histopathological classification of pseudomyxoma peritonei and the prognostic importance of PINCH protein.
Anticancer research 2012;32(4):1443-8.
2012: Caroline Haglund; Martin Höglund; Rolf Larsson; Anna Aleskog; Joachim Gullbo; Peter Nygren; Malin Wickström; Elin Lindhagen
In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues.
Cancer chemotherapy and pharmacology 2012;69(3):697-707.
2012: Sara Häggblad Sahlberg; Johan Lennartsson; Peter Nygren; Diana Spiegelberg; Bengt Glimelius; Bo Stenerlöw
The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines.
International journal of oncology 2012;40(1):176-84.
2011: Saadia Hassan; Rolf Larsson; Daniel Laryea; Stig Linder; Haile Mahteme; Walid Fayad; Jenny Felth; Mårten Fryknäs; Bengt Glimelius; Wilhelm Graf; Joachim Gullbo; Lars Påhlman; Linda Rickardson; Peter Nygren
Novel activity of acriflavine against colorectal cancer tumor cells.
Cancer science 2011;102(12):2206-13.
2011: Joachim Gullbo; Mårten Fryknäs; Linda Rickardson; Padraig Darcy; Maria Hägg; Malin Wickström; Sadia Hassan; Gunnar Westman; Slavica Brnjic; Peter Nygren; Stig Linder; Rolf Larsson
Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.
Biochemical pharmacology 2011;82(2):139-47.
2011: Peter Cashin; Dan Granberg; Per Hellman; Håkan Andréasson; Peter Nygren; Haile Mahteme
Appendiceal adenocarcinoids with peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy: a retrospective study of in vitro drug sensitivity and survival.
Clinical colorectal cancer 2011;10(2):108-12.
2011: Malin Wickström; Rolf Larsson; Peter Nygren; Joachim Gullbo
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
Cancer science 2011;102(3):501-8.
2010: Anne von Heideman; Ake Berglund; Rolf Larsson; Peter Nygren
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.
Cancer chemotherapy and pharmacology 2010;65(6):1165-72.
2010: Ake Berglund; Per Byström; Birgitta Johansson; Peter Nygren; Jan-Erik Frödin; Dorte Pedersen; Henry Letocha; Bengt Glimelius
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Medical oncology (Northwood, London, England) 2010;27(1):65-72.
2010: Kefei Hu; Saideh Berenjian; Rolf Larsson; Joachim Gullbo; Peter Nygren; Tanja Lövgren; Bror Morein
Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index.
International journal of nanomedicine 2010;5():51-62.
2010: Daniel Laryea; Joachim Gullbo; Anders Isaksson; Rolf Larsson; Peter Nygren
Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells.
Anti-cancer drugs 2010;21(1):33-42.
2009: Daniel Laryea; Anders Isaksson; Colin W Wright; Rolf Larsson; Peter Nygren
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.
Investigational new drugs 2009;27(5):402-11.
2009: J Hansson; Wilhelm Graf; Lars Påhlman; Peter Nygren; Haile Mahteme
Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009;35(2):202-8.
2009: Kristina Wiberg; Kristina Carlson; Anna Aleskog; Rolf Larsson; Peter Nygren; Elin Lindhagen
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.
Medical oncology (Northwood, London, England) 2009;26(2):193-201.
2008: Anna Aleskog; Maria Norberg; Peter Nygren; Linda Rickardson; Meena Kanduri; Gerard Tobin; Magnus Aberg; Mats G Gustafsson; Richard Rosenquist; Elin Lindhagen
Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.
Leukemia & lymphoma 2008;49(12):2333-43.
2008: Peter Nygren; Lars Sandman
[If you are young you get it, but if you are old you are left out. The significance of age for choice of treatment and priorities in cancer care].
Läkartidningen 2008;105(47):3417-9.
2008: Elin Lindhagen; Anna Eriksson; Malin Wickström; Katarina Danielsson; Birgitta Grundmark; Roger Henriksson; Peter Nygren; Anna Aleskog; Rolf Larsson; Mattias Höglund
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
European journal of haematology 2008;81(5):344-53.
2008: Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
Investigational new drugs 2008;26(3):195-204.
2008: Peter Nygren; Rolf Larsson
Predictive tests for individualization of pharmacological cancer treatment.
Expert opinion on medical diagnostics 2008;2(4):349-60.
2008: Elin Lindhagen; Peter Nygren; Rolf Larsson
The fluorometric microculture cytotoxicity assay.
Nature protocols 2008;3(8):1364-9.
2008: Peter Nygren; Lennart Blomqvist; Jonas Bergh; Gunnar Aström
Radiological assessment of tumour response to anti-cancer drugs: time to reappraise.
Acta oncologica (Stockholm, Sweden) 2008;47(2):316-8.
2007: Angelica Quartino; Mats O Karlsson; Agneta Freijs; Niclas Jonsson; Peter Nygren; Jörgen Kristensen; Elin Lindhagen; Rolf Larsson
Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.
Journal of clinical pharmacology 2007;47(8):1014-21.
2007: Elin Lindhagen; Linda Rickardson; Gary Elliott; Lorenzo Leoni; Peter Nygren; Rolf Larsson; Anna Aleskog
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.
Investigational new drugs 2007;25(4):297-303.
2007: Henrik Lindman; Gunnar Aström; Johan Ahlgren; Kenneth Villman; Carl Blomqvist; Peter Nygren; Jonas Bergh
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.
Acta oncologica (Stockholm, Sweden) 2007;46(2):165-71.
2007: Mårten Fryknäs; Sumeer Dhar; Fredrik Oberg; Linda Rickardson; Maria Rydåker; Hanna Göransson; Mats Gustafsson; Ulf Pettersson; Peter Nygren; Rolf Larsson; Anders Isaksson
STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines.
International journal of cancer. Journal international du cancer 2007;120(1):189-95.
2007: Malin Wickström; Katarina Danielsson; Linda Rickardson; Joachim Gullbo; Peter Nygren; Anders Isaksson; Rolf Larsson; Henrik Lövborg
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
Biochemical pharmacology 2007;73(1):25-33.
2006: Linda Rickardson; Mårten Fryknäs; Caroline Haglund; Henrik Lövborg; Peter Nygren; Mats G Gustafsson; Anders Isaksson; Rolf Larsson
Screening of an annotated compound library for drug activity in a resistant myeloma cell line.
Cancer chemotherapy and pharmacology 2006;58(6):749-58.
2006: Mårten Fryknäs; Linda Rickardson; Malin Wickström; Sumeer Dhar; Henrik Lövborg; Joachim Gullbo; Peter Nygren; Mats G Gustafsson; Anders Isaksson; Rolf Larsson
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
Journal of biomolecular screening 2006;11(5):457-68.
2006: Marie Sandström; Henrik Lindman; Peter Nygren; M Johansson; Jonas Bergh; Mats O Karlsson
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Cancer chemotherapy and pharmacology 2006;58(2):143-56.
2006: Martin Dreilich; Anna Lindkvist; Sumeer Dhar; Ylva Paulsson-Karlsson; Daniel Brattström; Peter Nygren; Linda Rickardson; Gunnar Wagenius; Michael Bergqvist
Telomerase activity is not a key determinant of sensitivity to standard cytotoxic drugs in human esophageal carcinoma cell lines.
Anti-cancer drugs 2006;17(5):503-9.
2006: Mariann Hedström; Anders Kreuger; Gustaf Ljungman; Peter Nygren; Louise von Essen
Accuracy of assessment of distress, anxiety, and depression by physicians and nurses in adolescents recently diagnosed with cancer.
Pediatric blood & cancer 2006;46(7):773-9.
2006: Henrik Lövborg; Fredrik Oberg; Linda Rickardson; Joachim Gullbo; Peter Nygren; Rolf Larsson
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
International journal of cancer. Journal international du cancer 2006;118(6):1577-80.
2005: Linda Rickardson; Mårten Fryknäs; Sumeer Dhar; Henrik Lövborg; Joachim Gullbo; M Rydåker; Peter Nygren; Mats G Gustafsson; Rolf Larsson; Anders Isaksson
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.
British journal of cancer 2005;93(4):483-92.
2005: Kenneth Villman; Carl Blomqvist; Rolf Larsson; Peter Nygren
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Anti-cancer drugs 2005;16(6):609-15.
2005: Peter Nygren; Kenneth Hande; Petty Kevin; Margaret Fedgchin; Kristien van Dyck; Anup Majumdar; Deborah Panebianco; Marina De Smet; Tuli Ahmed; M Gail Murphy; Keith M Gottesdiener; Veronique Cocquyt; Simon Van Belle
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Cancer chemotherapy and pharmacology 2005;55(6):609-16.
2005: Anna Aleskog; Rolf Larsson; Mattias Höglund; Jörgen Kristensen; Peter Nygren; Elin Lindhagen
In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
Anti-cancer drugs 2005;16(3):277-83.
2005: Christina Persson; Bengt Glimelius; Johan Rönnelid; Peter Nygren
Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study.
Nutrition (Burbank, Los Angeles County, Calif.) 2005;21(2):170-8.
2005: Marie Sandström; Henrik Lindman; Peter Nygren; Elisabet Lidbrink; Jonas Bergh; Mats O Karlsson
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):413-21.
2005: Peter Nygren; Halfdan Sørbye; Pia Osterlund; Per Pfeiffer
Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
Acta oncologica (Stockholm, Sweden) 2005;44(3):203-17.
2004: Anna Aleskog; Gerard Tobin; Anna Laurell; Ulf Thunberg; Elin Lindhagen; Göran Roos; Kenneth Nilsson; Peter Nygren; Christer Sundström; Mattias Höglund; Rolf Larsson; Richard Rosenquist
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
European journal of haematology 2004;73(6):407-11.
2004: Joachim Gullbo; Elin Lindhagen; Saadia Bashir-Hassan; Marcus Tullberg; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Manuel de la Torre; Kristina Luthman; Rolf Larsson
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
Investigational new drugs 2004;22(4):411-20.
2004: Henrik Lövborg; Peter Nygren; Rolf Larsson
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828.
Molecular cancer therapeutics 2004;3(5):521-6.
2004: Haile Mahteme; J Hansson; A Berglund; Lars Påhlman; Bengt Glimelius; Peter Nygren; Wilhelm Graf
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
British journal of cancer 2004;90(2):403-7.
2004: Peter Hovstadius; Elin Lindhagen; Sadia Hassan; Kenneth Nilsson; Helena Jernberg-Wiklund; Peter Nygren; Lise Binderup; Rolf Larsson
Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.
Anti-cancer drugs 2004;15(1):63-70.
2004: Joachim Gullbo; Henrik Lövborg; Sumeer Dhar; Agneta Lukinius; Fredrik Oberg; Kenneth Nilsson; Fredrik Björkling; Lise Binderup; Peter Nygren; Rolf Larsson
Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.
Anti-cancer drugs 2004;15(1):45-54.
2003: Joachim Gullbo; Charlotta Wallinder; Marcus Tullberg; Henrik Lövborg; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Kristina Luthman; Rolf Larsson
Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
Molecular cancer therapeutics 2003;2(12):1331-9.
2003: Nenad Sarapa; Margaret R Britto; William Speed; Maria Gabriella Jannuzzo; Massimo Breda; Christopher A James; MariaGrazia Porro; Maurizio Rocchetti; Alkvin Wanders; Haile Mahteme; Peter Nygren
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Cancer chemotherapy and pharmacology 2003;52(5):424-30.
2003: Joachim Gullbo; Sumeer Dhar; Kristina Luthman; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Rolf Larsson
Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
Anti-cancer drugs 2003;14(8):617-24.
2003: Joachim Gullbo; Malin Wickström; Marcus Tullberg; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Kristina Luthman; Rolf Larsson
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
Journal of drug targeting 2003;11(6):355-63.
2003: Anja Henningsson; Alex Sparreboom; Marie Sandström; Agneta Freijs; Rolf Larsson; Jonas Bergh; Peter Nygren; Mats O Karlsson
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1105-14.
2003: Joachim Gullbo; Marcus Tullberg; Jon Våbenø; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Rolf Larsson; Kristina Luthman
Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.
Oncology research 2003;14(3):113-32.
2003: Peter Nygren; R Larsson
Overview of the clinical efficacy of investigational anticancer drugs.
Journal of internal medicine 2003;253(1):46-75.
2002: Pernilla Martinsson; Sara Ekelund; Peter Nygren; Rolf Larsson
The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis.
British journal of pharmacology 2002;137(4):568-73.
2002: Sara Ekelund; Ingrid Persson; Rolf Larsson; Peter Nygren
Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.
Chemotherapy 2002;48(4):196-204.
2002: Sara Ekelund; Rolf Larsson; Peter Nygren
Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells.
Anticancer research 2002;22(4):2269-74.
2002: Anna Aleskog; Elin Jonsson; Rolf Larsson; Peter Nygren; Jörgen Kristensen; Christer Sundström; Mattias Höglund
In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma.
British journal of haematology 2002;117(3):563-8.
2002: Henrik Lövborg; Pernilla Martinsson; Joachim Gullbo; Sara Ekelund; Peter Nygren; Rolf Larsson
Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.
Biochemical pharmacology 2002;63(8):1491-8.
2002: Ake Berglund; Bengt Glimelius; Jonas Bergh; Ola Brodin; Marie-Louise Fjällskog; Hans Hagberg; Anne von Heideman; Rolf Larsson; Bengt Tholander; Manuel de la Torre; Gunnar Aström; Kjell Oberg; Gunnar Parö; Peter Nygren
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.
Medical oncology (Northwood, London, England) 2002;19(3):151-9.
2001: Pernilla Martinsson; G Liminga; Peter Nygren; Rolf Larsson
Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line.
Anti-cancer drugs 2001;12(8):699-705.
2001: S Ekelund; Peter Nygren; Rolf Larsson
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
Biochemical pharmacology 2001;61(10):1183-93.
2001: Sara Ekelund; A Sjöholm; Peter Nygren; Lise Binderup; Rolf Larsson
Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone).
European journal of pharmacology 2001;418(1-2):39-45.
2001: Bengt Glimelius; Peter Nygren; Gunilla Lamnevik
[Cytostatic therapy in cancer--a SBU report].
Läkartidningen 2001;98(16):1905-10.
2001: Pernilla Martinsson; Manuel de la Torre; Lise Binderup; Peter Nygren; Rolf Larsson
Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells.
European journal of pharmacology 2001;417(3):181-7.
2001: Elin Jonsson; Lena E Friberg; Mats O Karlsson; Saadia B Hassan; Peter Nygren; Jörgen Kristensen; B Tholander; Lise Binderup; Rolf Larsson
In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients.
Cancer letters 2001;162(2):193-200.
2001: Peter Ragnhammar; Bengt Brorsson; Peter Nygren; Bengt Glimelius
A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):391-411.
2001: Johan Permert; Larsolof Hafström; Peter Nygren; Bengt Glimelius
A systematic overview of chemotherapy effects in pancreatic cancer.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):361-70.
2001: Karl-Gunnar Janunger; Larsolof Hafström; Peter Nygren; Bengt Glimelius
A systematic overview of chemotherapy effects in gastric cancer.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):309-26.
2001: Peter Ragnhammar; Larsolof Hafström; Peter Nygren; Bengt Glimelius
A systematic overview of chemotherapy effects in colorectal cancer.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):282-308.
2001: Peter Nygren
What is cancer chemotherapy?
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):166-74.
2001: Peter Nygren; Bengt Glimelius
The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy--Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):155-65.
2001: Bengt Glimelius; Jonas Bergh; L Brandt; Bengt Brorsson; B Gunnars; Larsolof Hafström; Ulf Haglund; T Högberg; Karl-Gunnar Janunger; P E Jönsson; G Karlsson; E Kimby; Gunilla Lamnevik; S Nilsson; Johan Permert; Peter Ragnhammar; S Sörenson; Peter Nygren
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):135-54.
2001: Saadia B Hassan; Manuel de la Torre; Peter Nygren; Mats O Karlsson; Rolf Larsson; Elin Jonsson
A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828.
Anti-cancer drugs 2001;12(1):33-42.
2000: G Liminga; Pernilla Martinsson; B Jonsson; Peter Nygren; Rolf Larsson
Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB.
Biochemical pharmacology 2000;60(12):1751-9.
2000: Anne von Heideman; M Sandström; K Csoka; Bengt Tholander; Rolf Larsson; Jonas Bergh; Peter Nygren
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1301-7.
2000: E Jonsson; S Dhar; B Jonsson; Peter Nygren; W Graf; Rolf Larsson
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
European journal of cancer (Oxford, England : 1990) 2000;36(16):2120-7.
2000: Sumeer Dhar; Joachim Gullbo; K Csoka; E Eriksson; Kenneth Nilsson; P Nickel; Rolf Larsson; Peter Nygren
Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients.
European journal of cancer (Oxford, England : 1990) 2000;36(6):803-9.
1999: G Liminga; B Jonsson; Peter Nygren; Rolf Larsson
On the mechanism underlying calcein-induced cytotoxicity.
European journal of pharmacology 1999;383(3):321-9.
1999: Mats O Karlsson; V Molnar; Agneta Freijs; Peter Nygren; Jonas Bergh; Rolf Larsson
Pharmacokinetic models for the saturable distribution of paclitaxel.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(10):1220-3.
1999: H Fridborg; Elin Jonsson; Peter Nygren; Rolf Larsson
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic.
European journal of cancer (Oxford, England : 1990) 1999;35(3):424-32.
1998: Elin Jonsson; H Fridborg; Peter Nygren; Rolf Larsson
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
European journal of clinical pharmacology 1998;54(7):509-14.
1998: Rolf Larsson; Sumeer Dhar; Hans Ehrsson; Peter Nygren; Rolf Lewensohn
Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.
British journal of cancer 1998;78(3):328-35.
1998: Sara Ekelund; Peter Nygren; Rolf Larsson
Microphysiometry: new technology for evaluation of anticancer drug activity in human tumor cells in vitro.
Anti-cancer drugs 1998;9(6):531-8.
1998: Sumeer Dhar; Peter Nygren; G Liminga; C Sundström; Manuel de la Torre; K Nilsson; Rolf Larsson
Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance.
European journal of pharmacology 1998;346(2-3):315-22.
1997: K Csóka; Bengt Tholander; E Gerdin; M de la Torre; Rolf Larsson; Peter Nygren
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
International journal of cancer. Journal international du cancer 1997;72(6):1008-12.
1997: K Csóka; Sumeer Dhar; H Fridborg; Rolf Larsson; Peter Nygren
Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
Cancer 1997;79(6):1225-33.
1997: Elin Jonsson; H Fridborg; K Csóka; Sumeer Dhar; Christer Sundström; Peter Nygren; Rolf Larsson
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
British journal of cancer 1997;76(2):211-9.
1997: Pernilla Martinsson; Peter Nygren; H Fridborg; K Nilsson; Jörgen Kristensen; Rolf Larsson
Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies.
European journal of clinical pharmacology 1997;52(3):199-203.
1996: H Fridborg; Peter Nygren; Sumeer Dhar; K Csoka; Jörgen Kristensen; Rolf Larsson
In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Journal of experimental therapeutics & oncology 1996;1(5):286-95.
1996: Sumeer Dhar; Peter Nygren; K Csoka; Johan Botling; Kenneth Nilsson; Rolf Larsson
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
British journal of cancer 1996;74(6):888-96.
1996: Peter Ridefelt; Rolf Larsson; Peter Nygren; E Larsson; Kenneth Nilsson
Modulation of calcium signalling and proliferation in monoblastoid U-937 cells.
Anticancer research 1996;16(4A):1643-50.
1996: B Jonsson; G Liminga; K Csoka; H Fridborg; Sumeer Dhar; Peter Nygren; Rolf Larsson
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours.
European journal of cancer (Oxford, England : 1990) 1996;32A(5):883-7.
1995: K Csoka; Peter Nygren; W Graf; L Påhlman; Bengt Glimelius; Rolf Larsson
Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients.
International journal of cancer. Journal international du cancer 1995;63(3):356-60.
1995: G Liminga; Peter Nygren; Sumeer Dhar; Kenneth Nilsson; Rolf Larsson
Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: drug delivery by intracellular trapping.
Anti-cancer drugs 1995;6(4):578-85.
1995: K Csoka; Jan Liliemark; Rolf Larsson; Peter Nygren
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Seminars in oncology 1995;22(4 Suppl 11):47-53.
1995: Peter Nygren; K Csoka; B Jonsson; H Fridborg; Jonas Bergh; H Hagberg; Bengt Glimelius; Ola Brodin; B Tholander; A Kreuger
The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
British journal of cancer 1995;71(3):478-81.
1995: H Fridborg; Peter Nygren; Rolf Larsson
Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs.
Anti-cancer drugs 1995;6(1):64-9.
1994: Rolf Larsson; Peter Nygren
Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors.
Cancer 1994;74(10):2857-62.
1994: Jörgen Kristensen; Peter Nygren; Jan Liliemark; H Fridborg; A Killander; Bengt Simonsson; Gunnar Oberg; Rolf Larsson
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Leukemia 1994;8(10):1712-7.
1994: M Holmberg; C Sandberg; Peter Nygren; Rolf Larsson
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein.
Anti-cancer drugs 1994;5(5):598-600.
1994: K Csoka; Rolf Larsson; B Tholander; E Gerdin; M de la Torre; Peter Nygren
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
Gynecologic oncology 1994;54(2):163-70.
1994: Johan Botling; G Liminga; Rolf Larsson; Peter Nygren; Kenneth Nilsson
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.
International journal of cancer. Journal international du cancer 1994;58(2):269-74.
1994: H Fridborg; B Jonsson; Peter Nygren; K Csoka; Kenneth Nilsson; Gunnar Oberg; Jörgen Kristensen; Jonas Bergh; B Tholander; L Olsen
Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.
British journal of cancer 1994;70(1):11-7.
1994: G Liminga; Peter Nygren; Rolf Larsson
Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.
Experimental cell research 1994;212(2):291-6.
1994: H Fridborg; Rolf Larsson; Claes Juhlin; Jonas Rastad; Göran Akerström; K Backlin; Peter Nygren
P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
Anticancer research 1994;14(3A):1009-16.
1994: Peter Nygren; H Fridborg; K Csoka; Christer Sundström; M de la Torre; Jörgen Kristensen; Jonas Bergh; H Hagberg; Bengt Glimelius; Jonas Rastad
Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients.
International journal of cancer. Journal international du cancer 1994;56(5):715-20.
1994: Peter Nygren; H Hagberg; Bengt Glimelius; Christer Sundström; Jörgen Kristensen; I Christiansen; Rolf Larsson
In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 1():127-31.
1994: Rolf Larsson; H Fridborg; Jan Liliemark; K Csoka; Jörgen Kristensen; M de la Torre; Peter Nygren
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):1022-6.
1993: Rolf Larsson; Peter Nygren
Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model.
Anticancer research 1993;13(5C):1825-9.
1993: Rolf Larsson; H Fridborg; Jörgen Kristensen; Christer Sundström; Peter Nygren
In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA).
British journal of cancer 1993;67(5):969-74.
1993: Rolf Larsson; Peter Nygren
Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1208-12.
1992: Rolf Larsson; B Jonsson; K Csoka; Jörgen Kristensen; Kenneth Nilsson; Peter Nygren
Selective cytotoxic activity of cyclosporins against tumor cells from patients with B cell chronic lymphocytic leukemia.
European journal of pharmacology 1992;228(4):237-40.
1992: B Jonsson; Kenneth Nilsson; Peter Nygren; Rolf Larsson
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Anti-cancer drugs 1992;3(6):641-6.
1992: Peter Nygren; Jörgen Kristensen; B Jonsson; Christer Sundström; G Lönnerholm; A Kreuger; Rolf Larsson
Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia.
Leukemia 1992;6(11):1121-8.
1992: R Larssson; H Fridborg; K Csoka; Jonas Bergh; Peter Nygren
Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity.
Anticancer research 1992;12(5):1581-5.
1992: Rolf Larsson; Jörgen Kristensen; C Sandberg; Peter Nygren
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA).
International journal of cancer. Journal international du cancer 1992;50(2):177-85.
1992: Jörgen Kristensen; B Jonsson; Christer Sundström; Peter Nygren; Rolf Larsson
In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.
Medical oncology and tumor pharmacotherapy 1992;9(2):65-74.
1991: Peter Nygren; Rolf Larsson; A Gruber; C Peterson; Jonas Bergh
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
British journal of cancer 1991;64(6):1011-8.
1991: Peter Nygren; Rolf Larsson
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.
International journal of cancer. Journal international du cancer 1991;48(4):598-604.
1991: Rolf Larsson; Jonas Bergh; Peter Nygren
Combination of cyclosporin A and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin.
Anticancer research 1991;11(1):455-9.
1990: Rolf Larsson; Peter Nygren
Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein.
Cancer letters 1990;54(3):125-31.
1990: Rolf Larsson; Peter Nygren; M Ekberg; L Slater
Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay.
Leukemia 1990;4(8):567-71.
1990: Rolf Larsson; Peter Nygren
Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.
International journal of cancer. Journal international du cancer 1990;46(1):67-72.
1989: Rolf Larsson; Peter Nygren
A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture.
Anticancer research 1989;9(4):1111-9.
1989: Rolf Larsson; Peter Nygren; K Forsbeck; Erik Gylfe; Kenneth Nilsson
Early ionic events associated with phorbol ester induced differentiation and inhibition of cell growth in hematopoietic tumor cell lines.
Anticancer research 1989;9(1):1-7.
1988: K Forsbeck; Kenneth Nilsson; Peter Nygren; Rolf Larsson; Erik Gylfe; G Skoglund; Magnus Ingelman-Sundberg
Phorbol-ester-induced stable changes in the regulation of DNA synthesis and intracellular pH are accompanied by altered expression of protein kinase C in the monoblastoid cell line U-937.
International journal of cancer. Journal international du cancer 1988;42(2):284-8.
1988: K Forsbeck; Peter Nygren; Rolf Larsson; M Nilsson; Kenneth Nilsson; Erik Gylfe
Cytoplasmic pH is differently regulated in the monoblastic U-937 and erythroleukemic K-562 cell lines.
Experimental cell research 1988;176(1):96-106.
1987: Peter Nygren; Rolf Larsson; K Forsbeck; Kenneth Nilsson; Erik Gylfe
TPA induces cytoplasmic alkalinization in human monoblastic U-937 cells without activation of Na+/H+ exchange.
Experimental cell research 1987;171(1):265-9.